MAY 1 8 2006 336292.1Rev 2/06

15W 1644

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Lawrence J. Saubermann et al. In re application

Application No.

10/568.364

Filed

February 14, 2006

Confirmation No.

IMMUNOLOGIC ACTIVITY MEASURE(S) FOR T HELPER ON-

ASSOCIATED CONDITIONS

Examiner

Not Assigned

Attorney's Docket : BU-101XX

TC Art Unit: 1644

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on New 15, 2006

> Holliday C. Heine, Ph.D. Registration No. 34,346 Attorney for Applicant(s)

INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

It is desired to cite for the record in this application the enclosed references listed on the attached copy of PTO Form #1449. The paragraph(s) marked below are applicable to this Information Disclosure Statement.

(1) Pursuant to 37 C.F.R. § 1.97(b)(1) and (2), the attached [X] Information Disclosure Statement is being filed within three months of the filing date of the above identified national application or within three months of the date of entry of the national stage as set forth in 37 C.F.R. § 1.491 of the above

Application No.: 10/568,364 Filed: February 14, 2006 TC Art Unit: 1644

Confirmation No.: 1148

identified application. Accordingly, applicant(s) believes that no fee or statement under 37 C.F.R. § 1.97(e) is required.

These references were cited in the International Search Report (copy enclosed) of the corresponding International Application No. PCT/US2004/026236 filed on 10 August 2004. Copies of these references have been transmitted by the International Bureau.

- (2) Pursuant to 37 C.F.R. § 1.97(b)(3), applicant(s) believes the attached Information Disclosure Statement is being filed before the mailing date of a first Office action on the merits. Accordingly, applicant(s) believes that no fee or statement under 37 C.F.R. § 1.97(e) is required.
- [] (3) Pursuant to 37 C.F.R. § 1.97(b)(4), applicant(s) believes the attached Information Disclosure Statement is being filed before the mailing date of a first Office action after the filing of a request for continued examination under § 1.114. Accordingly, applicant(s) believes that no fee or statement under 37 C.F.R. § 1.97(e) is required.
- (4) Pursuant to 37 C.F.R. § 1.97(c), the attached Information Disclosure Statement is being filed before the mailing date of a final action or a notice of allowance and is accompanied by:
 [] a statement under 37 CFR § 1.97(e); or
 - [] the fee set forth in § 1.17(p).

PETITION UNDER 37 CFR § 1.97(d)

[] (5) Pursuant to 37 CFR § 1.97(d), applicant(s) hereby petitions the Commissioner to consider the attached Information Disclosure Statement which is being filed on or before payment of the issue fee. This petition is accompanied by a statement under 37 C.F.R. § 1.97(e) and the petition fee set forth in 37 C.F.R. § 1.17(b).

STATEMENT UNDER 37 C.F.R. § 1.97(e)(1)

[] (6) The undersigned hereby states that each item of information contained in the attached Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filling of this Information Disclosure Statement.

STATEMENT UNDER 37 C.F.R. § 1.97(e)(2)

Application No.: 10/568,364
Filed: February 14, 2006
TC Art Unit: 1644
Confirmation No.: 1148

[] (7) The undersigned hereby states that no item of information contained in the attached Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in the attached Information Disclosure Statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

Where the status of the application has changed, unknown to the applicant, such that the boxes checked are no longer applicable, the Commissioner is authorized to accept this submission with any additional fees required by that change charged to Deposit Account No. 23-0804.

The filing of this Information Disclosure Statement is not a representation by the undersigned as to personal knowledge of the contents of every word or phrase of the material enclosed or that reliance on other suitably trained professionals has not been made. The filing of this Information Disclosure Statement is not to be construed to be an admission that the information cited herewith is, or is considered to be, material to patentability as defined in 37 CFR \$1.56(b), or that Applicant(s) is(are) unable to provide an affidavit under 37 CFR \$1.131 swearing back of such information.

If a search report of a searching agency is enclosed identifying the nature of the relevance of each document, such a designation is deemed to satisfy 37 C.F.R. § 1.98(a)(3) even if in a foreign language because the codes are the same in all languages. However, applicant(s) does not necessarily adopt the position reflected by that report.

Application No.: 10/568,364
Filed: February 14, 2006
TC Art Unit: 1644
Confirmation No.: 1148

The Commissioner is hereby authorized to charge payment of any additional fees associated with this communication or credit any overpayment to Deposit Account No. 23-0804. Triplicate copies of this letter are enclosed.

Respectfully submitted,

LAWRENCE J. SAUBERMANN ET AL.

V: Holliday C. Heilne, Ph.D.
Registration Wo. 34,346
Attorney for Applicant(s)

WEINGARTEN, SCHURGIN,
GAGNEBIN & LEBOVICI LLP
Ten Post Office Square
Boston, Massachusetts 02109

Telephone: (617) 542-2290 Telecopier: (617) 451-0313

HCH/raw Enclosure



Date: May 15, 2006 Page 1 of 1

	U.S. DEPARTMENT OF COMMERCE			ATTY. DOCKET NO.		APPLICATION NO.			
(REV. 05/03)	93) PATENT AND TRADEMARK OFFICE			BU-101XX		10/568,364			
	INFORMATION DISCLOSURE CITATION								
	(Use several sheets if neces								
					APPLICANT:				
				Lawrence J.	Sauberma	ann et al			
				FILING DATE		TC ART UNIT			
			February 14, 2006 1644						
U.S. PATENT DOCUMENTS									
EXAMINER	DOCUMENT NUMBER	PUBLICATION/	NAME CLAS		CLASS	SUBCLASS	FILING DATE		
INITIAL		ISSUE DATE							
	US 6,203,997	3/20/2001	Romaschin et al						
	US 6,596,319	6/22/2003	Rang et al.						
	US								
	US								
	US								
	US								
	US								
FOREIGN PATENT DOCUMENTS									
	DOCUMENT NUMBER	DATE	COUNTRY		CLASS	SUBCLASS			
		ì					TRANSLATION		
		<u> </u>					YES	NO	
OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)									
Marie, C. "Reduced Ex Vivo Interlukin-8 Production by Neutrophils in Septic and Nonseptic Systemic Inflammatory									
	Response Syndrome", Blood, May 1998, Vol. 91, No. 9.								
EXAMINER	/David Saunders/ DATE CONSIDERED 03/24/2008								
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.									
HCH/raw 336294.1									